MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia-Reference-Cited by-同舟云学术

MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström’s macroglobulinemia

Published:2013-02-28 Issue:8 Volume:27 Page:1722-1728
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Jiménez C,Sebastián E,Chillón M C,Giraldo P,Mariano Hernández J,Escalante F,González-López T J,Aguilera C,de Coca A G,Murillo I,Alcoceba M,Balanzategui A,Sarasquete M E,Corral R,Marín L A,Paiva B,Ocio E M,Gutiérrez N C,González M,San Miguel J F,García-Sanz R

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201362.pdf

Reference46 articles.

1. Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF . Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 1998; 82: 1078–1081.

2. Herrinton LJ, Weiss NS . Incidence of Waldenstrom's macroglobulinemia. Blood 1993; 82: 3148–3150.

3. Garcia-Sanz R, Montoto S, Torrequebrada A, de Coca AG, Petit J, Sureda A et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 2001; 115: 575–582.

4. Phekoo KJ, Jack RH, Davies E, M°ller H, Schey SA . The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leukemia Res 2008; 32: 55–59.

5. Braggio E, Philipsborn C, Novak A, Hodge L, Ansell S, Fonseca R . Molecular pathogenesis of Waldenström macroglobulinemia. Haematologica 2012; 97: 1281–1290.

Cited by 231 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Waldenström Macroglobulinemia - A State-of-the-Art Review: Part 1: Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, risk stratification, and clinical problems.;Mediterranean Journal of Hematology and Infectious Diseases;2024-06-29

2. Bing–Neel syndrome, a rare manifestation of WM; a case report and review of literature;Clinical Case Reports;2024-06

3. Optimizing BTK Inhibition in Waldenström Macroglobulinemia;Journal of the National Comprehensive Cancer Network;2024-05

4. How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia;Blood;2024-04-25

5. Lymphoplasmacytic lymphoma and multiple myeloma coexisting in the same patient: a case series and literature review;Leukemia & Lymphoma;2024-03-19